

| | |
|-------------------------|--|
| 1. Record Nr. | UNINA9910864201303321 |
| Autore | Randall R. Lor |
| Titolo | Metastatic Bone Disease : An Integrated Approach to Patient Care |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing AG, , 2024 ©2024 |
| ISBN | 9783031520013 9783031520006 |
| Edizione | [2nd ed.] |
| Descrizione fisica | 1 online resource (388 pages) |
| Disciplina | 616.71 |
| Lingua di pubblicazione | Inglese |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Nota di contenuto | Intro -- Preface/Acknowledgments to the Second Edition -- Preface/Acknowledgments: A Better Place -- Contents -- Part I: The Problem -- 1: Bone Metastases: Epidemiology and Societal Effect -- Introduction -- Epidemiology of Metastatic Bone Disease -- Incidence of Bone Metastases -- Site of Bone Metastases -- Incidence of Skeletal-Related Complications -- Cancer Survival -- Implications of Increasing Survival -- Incidence of Pathological Fractures -- Predicting Pathological Fracture -- Impact on Survival of Pathological Fractures -- Quality of Life and Bone Metastases -- The Economic and Social Burden of Skeletal Related Events in Metastatic Bone Disease -- Summary -- References -- Part II: Biology of Metastases and Tissue of Origin Considerations -- 2: Mechanisms Underlying Osteolytic and Osteoblastic Bone Metastases -- The Bone as a Favorable Premetastatic Niche for Cancer -- Bone Remodeling -- Osteoblasts -- Osteoclasts -- Calcium Homeostasis -- Tumor Contribution to Pre-metastatic Niche in Bone -- Metastatic Homing -- Bone Colonization -- Tumor Dormancy -- Osteolytic and Osteoblastic Metastases -- Osteolytic Metastases: Breast Cancer as the Prototype -- Osteoblastic Metastases: Prostate Cancer as the Prototype -- Bone Metastasis Therapies -- Conclusions -- References -- 3: Tissue Engineered Models to Study Bone Metastasis and Metastatic Bone Disease -- Introduction -- Introduction to Tissue-Engineered Models -- Two- |

Dimensional (Monolayer) Culture Models -- 3D Culture Models -- Scaffold Composition to Model the Bone Microenvironment -- Fiber Alignment Within Engineered Materials to Guide Cell Fate -- Substrate Mechanical Properties Influence Cancer Cell Behavior -- Spheroids as 3D Cell Culture Models of Cancer -- Organ-On-a-Chip Models of Tumor Metastasis -- Preclinical Models of Metastatic Bone Disease -- Future Outlook -- References.

4: Biology of Bone Cancer Pain -- Introduction -- Biology of Cancer Pain -- Targeting Bone Cancer Pain -- Growth Factors -- Cytokines -- Ion Channels -- Osteoclast -- Conclusion -- References -- 5: Breast Cancer Bone Metastases -- Case Presentation -- Background -- Breast Cancer Characterization -- Staging -- Clinical Presentation of Breast Cancer Bony Metastasis -- Clinical Course -- Imaging in Breast Cancer Bone Metastases -- Treatment of Breast Cancer Bone Metastases -- Systemic Therapy -- Hormone Receptor Positive Metastatic Breast Cancer -- HER2-Positive Metastatic Breast Cancer -- Triple-Negative Metastatic Breast Cancer -- Osteoclast Inhibitors -- Local Therapy -- Analgesics -- Future Directions -- Case Follow-Up -- Summary -- References -- 6: Prostate Cancer Bone Metastases -- Introduction -- Biological Aspects Particular to Prostate Bone Metastasis -- Radiographic Appearance -- Histology -- Epidemiology and Prognosis -- Clinical Detection of Bone Metastasis -- Local Therapy -- Surgery -- Radiation -- Systemic Therapy -- Androgen Deprivation Therapy -- Chemotherapy -- Radioisotopes -- Immunotherapies -- PARP Inhibitors -- Adjunctive Therapy -- Osteoclast Inhibitors -- Conclusion -- References -- 7: Metastatic Primary Lung Cancer -- Introduction -- Work-Up -- Management of Disseminated Metastatic Disease -- Management of Limited Metastatic Disease -- Oligometastatic NSCLC to the Bone -- Conclusion -- References -- 8: Metastatic Bone Disease in Kidney Cancer -- Introduction -- Historical Overview of Management of Kidney Cancer -- Classification and Staging -- Treatment of RCC -- Treatment of Localized RCC -- Treatment of Advanced/Metastatic RCC -- Rationale for Cytoreductive Nephrectomy in mRCC -- Rationale for Metastasis-Directed Therapy in RCC -- Special Considerations for Bone Metastases in RCC -- Diagnosis of Bone Metastases. Bone Metastases as a Prognostic Outcome -- Treatment of RCC Bone Metastases -- Surgery -- Radiation Therapy -- Bisphosphonates and RANK Ligand Inhibitors -- Systemic Therapy -- Summary -- References -- 9: Thyroid Cancer Bone Metastasis -- Introduction -- Epidemiology of Thyroid Cancer -- Risk Factors -- Classification -- Distant Metastasis -- Distant Metastasis and Primary Tumor Characteristics -- Diagnosis of Bone Metastasis -- X-Ray Imaging -- Computed Tomography (CT) and Magnetic Resonance Imaging -- Iodine-131 (I-131) Whole-Body Scan -- 18FDG-PET Scanning -- Treatment of Bone Metastasis -- RAI and TSH Suppression -- Bisphosphonate and Denosumab Therapy -- Kinase Inhibitors -- Surgery -- Radiotherapy -- Percutaneous/Adjunctive Procedures -- Conclusion -- References -- 10: Introduction to Multiple Myeloma and Multiple Myeloma Bone Disease -- Epidemiology of Multiple Myeloma -- Spectrum of Plasma Cell Diseases -- Risk Stratification and Staging of Multiple Myeloma -- Frontline Systemic Therapy for MM -- Induction Therapy for Newly Diagnosed MM -- The Role of Autologous Stem Cell Transplant in NDMM -- Induction Therapy for Newly Diagnosed Transplant-Ineligible MM -- Consolidation and Maintenance Therapy in MM -- Treatment of Relapsed Disease -- Bone Disease in Multiple Myeloma -- Pathogenesis of Bone Disease in MM -- Treatment of Bone Disease in MM -- References -- Part III: Work-Up for Patients with Suspected Metastatic Bone Disease -- 11: Evaluation of the Patient

with Carcinoma of Unknown Origin Metastatic to Bone -- Introduction -- Discussion -- References -- 12: Biopsy Considerations -- Introduction -- Indications for Biopsy -- Procedural Techniques -- Biopsy Methods -- Incisional Biopsy -- Core Needle Biopsy -- Fine-Needle Aspiration -- Specimen Handling -- Summary -- References -- Part IV: Medical Therapy.

13: Bisphosphonates, Denosumab, and Anabolic Agents in the Treatment of Metastatic Bone Disease -- References -- 14: Biotargeting in Metastatic Bone Disease -- Biotargeting in Breast Cancer -- Biotargeting in Prostate Cancer -- Biotargeting in Thyroid Cancer -- Biotargeting in Lung Cancer -- Biotargeting in Renal Cancer -- Biotargeting in Multiple Myeloma -- Biotargeting in Lymphoma -- References -- Part V: Supportive Oncology -- 15: Psychosocial Considerations for Patients with Metastatic Bone Disease -- Physical -- Psychosocial Screening, Assessment and Treatment -- Depression and Anxiety -- Post-Traumatic Stress Disorder -- Suicide Ideation -- Substance Abuse -- Psychiatry -- Spirituality and Religion -- Diversity -- Integrated and Complementary Medicine -- End-of-Life Care Planning and Decision-Making -- Conclusion -- References -- 16: Pain Management in Metastatic Bone Disease -- Introduction -- Clinical Presentation -- Medical Treatment -- Nonsteroidal Anti-Inflammatory Drugs -- Corticosteroids -- Full Agonist Opioids -- Partial Agonist Opioids -- Bisphosphonates and Denosumab -- Tricyclic Antidepressants -- Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) -- Ketamine Therapy -- Radiation Therapy -- Interventional Pain Medicine and Bone Pain -- OsteoCool -- High-Frequency Ultrasound -- Intrathecal Therapy -- Electrochemotherapy -- Vertebral Augmentation and Stabilization -- Conclusion(s) -- References -- 17: When Is Hospice Appropriate? The Role for Hospice in Palliating Patients with Bone Metastases -- The Imperative of Palliative Care in Metastatic Bone Disease -- The Evolution of Hospice and Palliative Care -- Introduction -- Case Study -- Case Commentary -- Opportunities for Palliative Care Integration -- Conclusion -- References -- 18: PROs -- Introduction -- Outcome Measurement Terms and Definitions -- Psychometrics -- Definitions. Health Status Vs. Health: Related Quality-of-Life Measure -- Legacy, Disease-Specific, Location-Specific Vs. Generic Measures -- Orthopedic Oncology-Specific Patient-Reported Outcome Measures -- Musculoskeletal Tumor Society (MSTS) Scoring System -- Toronto Extremity Salvage Score (TESS) -- Bone Metastasis Quality of Life (BOMET-QoL) -- Generic Patient-Reported Outcome Measures -- Short-Form 36 (SF-36) -- Patient-Reported Outcome Measurement Information System (PROMIS®) -- Patient-Reported Preference Measures (PRPMs) -- References -- Part VI: Radiation Oncology -- 19: Current and Emerging Modalities -- Radiotherapy -- History -- Basic Radiobiology and Physics -- Radiotherapy for Bone Metastases -- Indications -- Mechanism of Pain Relief with RT -- Preparation for Treatment Delivery -- Radiotherapy for Spinal Cord Compression -- Conventional Radiation Therapy for Bone Metastases -- Single Versus Multiple Fractions -- Intensity Modulated Radiation Therapy (IMRT) -- Stereotactic Body Radiation Therapy (SBRT) -- Treatment by Histology -- Timing of Surgery and Radiotherapy -- Re-Irradiation -- Oligometastatic and Oligoprogressive Bony Metastatic Disease -- Conclusions -- References -- Part VII: Interventional Oncology -- 20: Ablation and Cementation Technologies -- Introduction -- Vertebral Augmentation -- Technical Aspects of VA -- Percutaneous Ablation -- Cryoablation -- Microwave -- Radiofrequency -- Thermal Protection -- Pelvic/Sacrum Stabilization -- References -- Part VIII: Principles of

Orthopedic Surgical Oncology -- 21: Issues Facing the Established Metastatic Bone Disease Patient: Timing/Indications for Surgery -- Introduction -- Perioperative Risk Assessment of the Metastatic Bone Disease Patient -- Survival Estimation: Useful Guidance or Exercise in Futility? -- Timing: All Surgeries Are Not Created Equal. Coordination with Chemotherapy and Radiation.
